Table 3 Comparison of clinical characteristics between CRKP group and CSKP group
Items | CRKP (n = 164) | CSKP (n = 328) | Z /χ2 | P value |
|---|---|---|---|---|
Male | 110(67.1%) | 195(59.5%) | 2.696 | 0.101 |
Age (years) | 56(29) | 59(19) | −0.103 | 0.918 |
Previous hospitalization | 121(73.8%) | 214(65.2%) | 3.667 | 0.056 |
Hospital stay (days) | 31(30) | 19(19) | −5.973 | <0.001 |
Hospital stay before bacteremia (days) | 14(20) | 4(12) | −8.556 | <0.001 |
APACHE II score | 12(6) | 8(5) | −9.025 | <0.001 |
ICU admission | 116(70.7%) | 58(17.7%) | 134.604 | <0.001 |
Use of systemic steroids | 46(28%) | 68(20.7%) | 3.288 | 0.070 |
Chemotherapy/Radiotherapy | 30(18.3%) | 72(22%) | 0.890 | 0.345 |
Use of immunosuppressant | 34(20.7%) | 79(24.1%) | 0.695 | 0.404 |
Hypertension | 72(43.9%) | 112(34.1%) | 4.445 | 0.035 |
Coronary heart disease | 37(22.6%) | 67(20.4%) | 0.299 | 0.585 |
Diabetes mellitus | 34(20.7%) | 124(37.8%) | 14.619 | <0.001 |
COPD | 14(8.5%) | 9(2.7%) | 8.233 | 0.004 |
Renal diseases | 22(13.4%) | 20(6.1%) | 7.497 | 0.006 |
Autoimmune diseases | 7(4.3%) | 10(3.0%) | 0.487 | 0.485 |
Solid tumor | 19(11.6%) | 45(13.7%) | 0.440 | 0.507 |
Hematologic malignancy | 24(14.6%) | 55(16.8%) | 0.369 | 0.543 |
Enema | 14(8.5%) | 9(2.7%) | 8.233 | 0.004 |
Nasogastric catheter | 117(71.3%) | 76(23.2%) | 106.419 | <0.001 |
Urinary catheter | 126(76.8%) | 95(29%) | 101.245 | <0.001 |
CVC | 142(86.6%) | 126(38.4%) | 102.298 | <0.001 |
Peripheral arterial catheter | 34(20.7%) | 17(5.2%) | 28.499 | <0.001 |
Blood purification | 36(22.0%) | 11(3.4%) | 43.766 | <0.001 |
Tracheal cannula | 94(57.3%) | 39(11.9%) | 114.383 | <0.001 |
Tracheostomy | 35(21.3%) | 21(6.4%) | 24.191 | <0.001 |
Non-invasive ventilation | 22(13.4%) | 15(4.6%) | 12.215 | <0.001 |
Gastroscopy | 6(3.7%) | 6(1.8%) | 0.865 | 0.352 |
Colonoscopy | 2(1.2%) | 1(0.3%) | 0.377 | 0.539 |
Bronchoscopy | 35(21.3%) | 4(1.2%) | 60.654 | <0.001 |
Sputum suction | 102(62.2%) | 48(14.6%) | 116.699 | <0.001 |
Thoracentesis | 37(22.6%) | 9(2.7%) | 50.660 | <0.001 |
Abdominocentesis | 19(11.6%) | 5(1.5%) | 23.851 | <0.001 |
Bone marrow puncture | 26(15.9%) | 56(17.1%) | 0.117 | 0.732 |
Lumbar puncture | 24(14.6%) | 24(7.3%) | 6.649 | 0.01 |
Previous surgery | 87(53.0%) | 82(25.0%) | 38.144 | <0.001 |
Abdominal surgery | 50(30.5%) | 88(26.8%) | 0.725 | 0.394 |
Enteral nutrition | 80(48.8%) | 44(13.4%) | 72.541 | <0.001 |
Parenteral nutrition Previous use of antibiotics | 95(57.9%) | 73(22.3%) | 61.866 | <0.001 |
Any antibiotics | 158(96.3%) | 229(69.8%) | 45.822 | <0.001 |
Carbapenems | 96(58.5%) | 44(13.4%) | 109.342 | <0.001 |
Glycopeptides | 61(37.2%) | 24(7.3%) | 68.293 | <0.001 |
Quinolones | 80(48.8%) | 85(25.9%) | 25.646 | <0.001 |
3rd/4th generation cephalosporins | 30(18.3%) | 47(14.3%) | 1.301 | 0.254 |
1st/2nd generation cephalosporins | 23(14.0%) | 42(12.8%) | 0.142 | 0.706 |
Penicillins | 6(3.7%) | 21(6.4%) | 1.587 | 0.208 |
β-lactamase inhibitor | 103(62.8%) | 104(31.7%) | 43.383 | <0.001 |
Aminoglycosides | 7(4.3%) | 4(1.2%) | 3.359 | 0.067 |
Linezolid | 19(11.7%) | 5(1.5%) | 24.044 | <0.001 |
Tigecycline | 38(23.2%) | 10(3%) | 50.280 | <0.001 |
Daptomycin | 3(1.8%) | 0(0.0%) | 3.396 | 0.065 |
Nitroimidazoles | 8(4.9%) | 13(4.0%) | 0.224 | 0.636 |
KP detection in other sites Outcome | 108(65.9%) | 78(23.8%) | 82.311 | <0.001 |
Death | 72(43.9%) | 49(14.9%) | 49.456 | <0.001 |